HZ-S109

HZ-S109 is an orally bioavailable targeted protein degrader (PROTAC) developed by HealZen Therapeutics (Hangzhou HeZheng Pharmaceutical) using its proprietary DaTProD® platform. It specifically targets Hematopoietic Progenitor Kinase 1 (HPK1, also known as MAP4K1), which is a negative regulator of T cell receptor signaling. By inducing the proteasomal degradation of HPK1, HZ-S109 aims to enhance T cell activation and anti-tumor immune responses. Preclinical studies have demonstrated that HZ-S109 exhibits potent degradation with DC50 values lower than 10 nM across various cell types, including Jurkat and CAR-T cells, while maintaining high selectivity over other family members. In syngeneic mouse models, oral administration of HZ-S109 has shown robust tumor growth inhibition both as a monotherapy and in combination with PD-L1 antibodies.

Other names

HPK1-targeted protein degraderHPK-1-targeted protein degraderHPK 1-targeted protein degraderMAP4K1 degraderMAP-4K1 degraderMAP 4K1 degrader